 0 Table of Contents |
  1 IDEA4RC FHIR IG - Home Page |
  2 IDEA4RC Model Overview |
  3 IDEA4RC Detailed ERD Model |
  4 IDEA4RC Logical Models |
  5 Useful Downloads |
  6 Condition-secondaryCancer-eu-i4rc Relationships |
  7 Encounter-eu-i4rc Relationships |
  8 Condition-primaryCancer-eu-i4rc Relationships |
  9 sarcoma-cancer-stage-group Relationships |
  10 hn-cancer-stage-group Relationships |
  11 episodeOfCare-eu-i4rc Relationships |
  12 MedicationAdministration-eu-i4rc Relationships |
  13 Subject Relationships |
  14 PatientFollowUp Relationships |
  15 EpisodeEvent Relationships |
  16 HospitalPatientRecords Relationships |
  17 CancerEpisode Relationships |
  18 AdverseEvent Relationships |
  19 GeneticTestExpression Relationships |
  20 Surgery Relationships |
  21 Radiotherapy Relationships |
  22 Artifacts Summary |
   22.1 Adverse Event |
   22.2 Cancer Episode |
   22.3 Episode Event |
   22.4 Genetic Test Expression |
   22.5 Hospital Patient Records |
   22.6 Patient |
   22.7 Patient Follow-Up |
   22.8 Radiotherapy |
   22.9 Surgery |
   22.10 Systemic Treatment |
   22.11 Cancer Episode Model to this guide Map |
   22.12 Episode Event Model to this guide Map |
   22.13 Genetic Test Expression Model to this guide Map |
   22.14 Genetic Test to this guide Map |
   22.15 Hospital Patient Records Model to this guide Map |
   22.16 Patient (Subject) Model to this guide Map |
   22.17 Patient Follow up Model to this guide Map |
   22.18 Radiotherapy Model to this guide Map |
   22.19 Surgery Model to this guide Map |
   22.20 Observation: Alcohol use |
   22.21 Observation: Cancer Treatment |
   22.22 Observation: Charlson Comorbidity Index |
   22.23 Observation: Comorbidities |
   22.24 Observation: ECOG Performance Status |
   22.25 Observation: Karnofsky Performance Status |
   22.26 Observation: Occurrence of the other cancer |
   22.27 Observation: Tobacco use |
   22.28 Patient: IDEA4RC |
   22.29 Condition: Metastatic Cancer |
   22.30 Condition: Primary Cancer |
   22.31 Observation: Diagnosis details |
   22.32 Observation: Head Neck Cancer Stage Group |
   22.33 Observation: Localized Category (Stage, Sarcoma) |
   22.34 Observation: LocoRegional Category (Stage, Sarcoma) |
   22.35 Observation: Radiological Extra-nodal extension (rENE) |
   22.36 Observation: Sarcoma Cancer Stage Group |
   22.37 Observation: TNM Distant Metastases Category |
   22.38 Observation: TNM Primary Tumor Category |
   22.39 Observation: TNM Regional Nodes Category |
   22.40 Encounter: IDEA4RC |
   22.41 Observation: date of the last contact |
   22.42 Observation: Status at the Last Follow Up |
   22.43 Procedure: Surgery |
   22.44 Procedure: Radiotherapy |
   22.45 MedicationAdministration: Chemotherapy |
   22.46 EpisodeOfCare: IDEA4RC |
   22.47 Clinical Stage |
   22.48 Diagnosis |
   22.49 Disease Extent |
   22.50 Drugs for Treatments |
   22.51 Isolated Limb Perfusion |
   22.52 Overall Treatment Response |
   22.53 Pathological Stage |
   22.54 Regional Deep Hyperthemia |
   22.55 AdverseEvent: IDEA4RC |
   22.56 Bundle: IDEA4RC |
   22.57 Observation: test results |
   22.58 Observation: Yes / No assertions |
   22.59 Procedure: Other Treatment |
   22.60 Body Location Qualifier |
   22.61 Condition related to resource |
   22.62 Laterality Qualifier |
   22.63 Performed Timing |
   22.64 Previous Status |
   22.65 Race Extension |
   22.66 Radiotherapy Dose Delivered To Volume Extension |
   22.67 Radiotherapy Energy or Isotope |
   22.68 Radiotherapy Modality And Technique Extension |
   22.69 Radiotherapy Modality Extension |
   22.70 Radiotherapy Number of Sessions Extension |
   22.71 Radiotherapy Technique Extension |
   22.72 Relapse Type |
   22.73 Same custodian flag |
   22.74 Affected Organs (surgery) |
   22.75 Alcohol Usage Status: Athena |
   22.76 Alcohol Usage Status: SNOMED CT |
   22.77 Antineoplastic and immunostimulating agents |
   22.78 Beam Quality |
   22.79 Body site qualifier |
   22.80 Calculated|Estimated |
   22.81 Cancer Chondro Osseous Tumours: Athena |
   22.82 Cancer diagnosis: Athena |
   22.83 Cancer Endometrial stromal and related Tumors: Athena |
   22.84 Cancer Event Type: Athena |
   22.85 Cancer Histology Adenocarcinoma: Athena |
   22.86 Cancer Histology Neuroendocrine: Athena |
   22.87 Cancer Histology Odontogenic Carcinoma: Athena |
   22.88 Cancer Histology SNUC: Athena |
   22.89 Cancer Histology Squamous: Athena |
   22.90 Cancer Histology Subgroup Adipocytic Tumours: Athena |
   22.91 Cancer Histology Subgroup Fmt Tumours: Athena |
   22.92 Cancer Histology Subgroup So called Fibrohistiocytic Tumours: Athena |
   22.93 Cancer Miscellanious mesenchimal tumors: Athena |
   22.94 Cancer Mixed epithelial and mesenchymal tumours: Athena |
   22.95 Cancer Pericytic Perivascular Tumours: Athena |
   22.96 Cancer Peripheral Nerve Sheath Tumors: Athena |
   22.97 Cancer Skeletal Muscle Tumours: Athena |
   22.98 Cancer Smooth Muscle Tumours: Athena |
   22.99 Cancer Stage Grading: Athena |
   22.100 Cancer Stage Group Value: Athena |
   22.101 Cancer Stage Group: Athena |
   22.102 Cancer Tumors Of Uncertain Differentiation: Athena |
   22.103 Cancer undif. small round cell sarcomas of bone and soft tissue: Athena |
   22.104 Cancer Vascular Tumours: Athena |
   22.105 Chemotherapy cumulative dose units |
   22.106 Comorbidities: Athena |
   22.107 Comorbidities: SNOMED |
   22.108 Country: athena |
   22.109 Current Smoking Status: Athena |
   22.110 ECOG Performance Status |
   22.111 Event Type |
   22.112 Extranodal Extension |
   22.113 Gender: Athena |
   22.114 Genetic Tests performed (Yes/no/Unk) |
   22.115 Genito urinary subsite: Athena |
   22.116 Hypopharynx subsite: Athena |
   22.117 Hypopharynx subsite: Snomed CT |
   22.118 Intra abdominal subsite: Athena |
   22.119 Intra thoracic subsite : Athena |
   22.120 Larynx subsite: Athena |
   22.121 Larynx subsite: Snomed CT |
   22.122 Lip subsite: Athena |
   22.123 Lip subsite: Snomed CT |
   22.124 Margins After Surgery |
   22.125 Metastatis: Athena |
   22.126 Nasal cavity and paranasal sinuses subsite: Athena |
   22.127 Nasal cavity and paranasal sinuses subsite: Snomed CT |
   22.128 Nasopharynx subsite: Athena |
   22.129 Nasopharynx subsite: Snomed CT |
   22.130 Not Performed|Unknown |
   22.131 Observation Codes for Distant Metastases Category |
   22.132 Observation Codes for Primary Tumor Category |
   22.133 Observation Codes for Regional Node Category |
   22.134 Occurrence of other cancer |
   22.135 Oral cavity subsite: Athena |
   22.136 Oral cavity subsite: Snomed CT |
   22.137 Oropharynx subsite: Athena |
   22.138 Oropharynx subsite: Snomed CT |
   22.139 Pathological M |
   22.140 Pathological N |
   22.141 Pathological T |
   22.142 Positive-Negative-No Test: Athena |
   22.143 Race |
   22.144 Radiotherapy Device Type |
   22.145 Reason For End Of Treatment |
   22.146 Sarcoma Staging: localized disease |
   22.147 Sarcoma Staging: loco-regional category |
   22.148 Setting Radiotherapy |
   22.149 Simple measures |
   22.150 Site of metastasis |
   22.151 Site rare (IDEA4RC) |
   22.152 Smoking Status: LOINC |
   22.153 Status at the Last Follow Up |
   22.154 Subsites: Athena |
   22.155 Subsites: SNOMED CT |
   22.156 Surgery Complication |
   22.157 Surgery Intention |
   22.158 Surgery Outcome |
   22.159 Surgical Complications |
   22.160 Surgical Procedure Category |
   22.161 Surgical Procedure Type |
   22.162 TNM Distant Metastases Category Value Set |
   22.163 TNM Primary Tumor Category Value Set |
   22.164 TNM Regional Nodes Category Value Set |
   22.165 Tobacco Product |
   22.166 Treatment completed as planned |
   22.167 Treatment Response |
   22.168 Treatment Setting |
   22.169 Treatment Technique |
   22.170 Trunk wall subsite: Athena |
   22.171 Type of Biopsy |
   22.172 Type of Diagnosis |
   22.173 Type of surgical approach |
   22.174 Type of Systemic Treatment |
   22.175 Type of Treatment |
   22.176 Types of Yes/No observations |
   22.177 Upper and Lower limbs subsite: Athena |
   22.178 Yes-No-Unk: Athena |
   22.179 IDEA4RC Code System |
   22.180 HN Stage Model to this guide Map |
   22.181 Other Treatment to this guide Map |
   22.182 Radiotherapy Model to this guide Map |
   22.183 Stage Model to this guide Map |
   22.184 Actor: Head and Neck |
   22.185 Actor: Sarcoma |
   22.186 Condition: Grade 2 tumor with several body sites and evidences |
   22.187 Condition: Metastasis bone and pleura |
   22.188 Condition: NOT CLEAR WHAT IT REPRESENTS..TO BE DISCUSSED |
   22.189 Condition: Stable Disease |
   22.190 encounter-id-14 |
   22.191 EpisodeOfCare |
   22.192 GOFSH-GENERATED-id-28 |
   22.193 GOFSH-GENERATED-id-30 |
   22.194 GOFSH-GENERATED-id-36 |
   22.195 Observation: Alcohol use |
   22.196 Observation: BMI |
   22.197 Observation: C reactive protein Positive |
   22.198 Observation: Charlson Comorbidity Index |
   22.199 Observation: comorbidity |
   22.200 Observation: date of the last contact |
   22.201 Observation: Diagnosis |
   22.202 Observation: Dimension of Tumor |
   22.203 Observation: Distant metastases clinical M1 |
   22.204 Observation: Distant metastases pathology M1 |
   22.205 Observation: ECOG Performance Status score |
   22.206 Observation: Epstein Barr virus DNA Negative |
   22.207 Observation: gene Mutation Analysis Performed yes |
   22.208 Observation: Human papilloma virus Negative |
   22.209 Observation: immunohiostochemestry analysis performed |
   22.210 Observation: Karnofsky Performance Status score |
   22.211 Observation: Number of mitoses per HPF |
   22.212 Observation: Occurrence of other Cancer: Hamartoma |
   22.213 Observation: Primary tumor clinical T0 |
   22.214 Observation: Primary tumor pathological T0 |
   22.215 Observation: Radiological Extra-nodal extension |
   22.216 Observation: Regional lymph nodes Clinical N1 |
   22.217 Observation: Regional lymph nodes pathology N3b |
   22.218 Observation: Surgery treatment occurred |
   22.219 Observation: TNM clinical stage grouping |
   22.220 Observation: TNM pathology stage grouping |
   22.221 Observation: Tobacco use panel |
   22.222 Patient: race extension |
   22.223 Procedure: Isolated limb perfusion |